Inhibrx Biosciences (INBX) Leases (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Leases for 3 consecutive years, with $6.0 million as the latest value for Q3 2025.
- On a quarterly basis, Leases rose 293.7% to $6.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.0 million, a 293.7% increase, with the full-year FY2024 number at $7.3 million, up 148.58% from a year prior.
- Leases was $6.0 million for Q3 2025 at Inhibrx Biosciences, down from $6.5 million in the prior quarter.
- In the past five years, Leases ranged from a high of $7.3 million in Q4 2024 to a low of $1.5 million in Q3 2024.
- A 3-year average of $4.7 million and a median of $6.0 million in 2025 define the central range for Leases.
- Peak YoY movement for Leases: skyrocketed 148.58% in 2024, then soared 293.7% in 2025.
- Inhibrx Biosciences' Leases stood at $3.0 million in 2023, then surged by 148.58% to $7.3 million in 2024, then fell by 18.18% to $6.0 million in 2025.
- Per Business Quant, the three most recent readings for INBX's Leases are $6.0 million (Q3 2025), $6.5 million (Q2 2025), and $6.9 million (Q1 2025).